Prosecution Insights
Last updated: November 04, 2026
Application No. 18/875,163

USE OF BIOLOGICAL MATERIAL IN PREPARING PRODUCT FOR LIMITING gastric volume

Non-Final OA §112
Filed
Dec 16, 2024
Priority
Jun 17, 2022 — CN 202210691945.7 +1 more
Examiner
COX, THADDEUS B
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Shanghai Zhuoruan Medical Technologies Co. Ltd.
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
11m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
914 granted / 1186 resolved
+7.1% vs TC avg
Strong +19% interview lift
Without
With
+18.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
49 currently pending
Career history
1238
Total Applications
across all art units

Statute-Specific Performance

§101
6.6%
-33.4% vs TC avg
§103
32.4%
-7.6% vs TC avg
§102
21.2%
-18.8% vs TC avg
§112
32.7%
-7.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1186 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Claim Objections Claim 24 is objected to because of the following informalities: in line 2, “biological material is single-region reinforcement or multi-region reinforcement” should apparently read --the biological material is a single-region reinforcement or a multi-region reinforcement--. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 21-33 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 21 recites the limitation "the residual stomach" in lines 7-8. There is insufficient antecedent basis for this limitation in the claim. Claim 21 also recites the limitation "a reinforcement" in line 8. It is not clear if this is intended to be the same as the “reinforce a gastric wall” previously recited in the claim or to be a separate element. Claim 21 also recites the limitation “wherein the biological material is configured to wrap a surface of the stomach, to reinforce a gastric wall by completely or partially wrapping a circumference of the residual stomach, wherein a reinforcement is in a range of above 20% of the circumference of the residual stomach” in lines 6-9. It is not clear if this is intended to positively recite a step of the claimed method or if it is merely intended to recite a capability of the biological material. Claim 21 also recites the limitation “a reinforcement is in a range of above 20% of the circumference” in the last two lines. It is not clear what is meant by this limitation; e.g., what aspect/parameter of the reinforcement is in this range? Suggested language for claim 21 would be: --A method for limiting volume of a remaining stomach following gastric volume reduction surgery, comprising: wrapping anterior and posterior walls of the remaining stomach with a biological material, wherein the biological material wraps a surface of the remaining stomach to reinforce a gastric wall by completely or partially wrapping a circumference of the remaining stomach, wherein the reinforcement wraps at least 20% of the circumference of the remaining stomach; wherein the biological material is a decellularized matrix, and has a non-uniform thickness ranging from 0.05 to 2 mm; and wherein the biological material is provided with through holes with a diameter of 0.1 to 20 mm--. If Applicant chooses to adopt this suggestion (or similar language), claims 25 and 32 may need to be amended as well to adopt the same language (e.g., “the remaining stomach” instead of “the stomach” and “the volume of the remaining stomach” instead of “the stomach volume”). Claim 26 recites the limitation "the shape" in line 1. There is insufficient antecedent basis for this limitation in the claim. Claim 26 also recites the limitation "the through hole" in line 1. It is not clear which of the multiple through holes this is intended to refer to. Claim 27 recites the limitations “all over” and “in a part of regions.” These terms are relative terms which render the claim indefinite. The terms are not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. It is not clear what is meant by these limitations or what the metes and bounds would be. Claim 31 recites the limitation "the surface [of the biological material]" in line 1. There is insufficient antecedent basis for this limitation in the claim. Claim 32 recites the limitation “wherein the biological material is used for preparing a product for limiting the stomach volume after gastric volume reduction surgery.” It is not clear if this is intended to positively recite a step of the claimed method or if it is merely intended to recite a capability of the biological material. Claims 22-33 are rejected by virtue of their dependence upon at least one rejected base claim. Allowable Subject Matter Claims 21-33 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. The following is a statement of reasons for the indication of allowable subject matter: Gabbay (U.S. Pub. No. 2002/0091395 A1) is taken to be the closest prior art of record. Gabbay teaches a method for limiting stomach volume that comprises wrapping walls of a stomach with a biocompatible material, wherein the biocompatible material is provided with through holes of various sizes and shapes, and is configured to completely wrap a circumference of the stomach. The biocompatible material may be a biological material, such as derived from pericardium. However, Gabbay fails to teach that the biological material is a decellularized matrix, with a non-uniform thickness of the recited dimensions, or that the through holes have the recited diameters. While the use of a decellularized matrix in a method of implantation is broadly known in the art, none of the prior art of record teaches or reasonably suggests using a decellularized matrix in such a method, wherein the decellularized matrix also includes a non-uniform thickness of the recited dimensions and through holes of the recited diameters. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Waldrep (U.S. Pub. No. 2011/0257760 A1) teaches a similar method that uses a biological material that can comprise human acellular tissue or bovine pericardium. Manos et al. (U.S. Pub. No. 2023/0107981 A1) and Schauer et al. (U.S. Pub. No. 2013/0331642 A1) also teach similar methods that use a biological material that can comprise pericardial tissue. Any inquiry concerning this communication or earlier communications from the examiner should be directed to THADDEUS B COX whose telephone number is (571)270-5132. The examiner can normally be reached M-F 9am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jason M. Sims can be reached at (571)272-7540. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /THADDEUS B COX/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Dec 16, 2024
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773570
EEG BASED MULTI-FREQUENCY STIMULATION
3y 3m to grant Granted Oct 27, 2026
Patent 12773160
TUMESCENSE MONITORING SYSTEM FOR DIAGNOSING ERECTILE DYSFUNCTION AND METHODS OF USE
3y 7m to grant Granted Oct 27, 2026
Patent 12773519
SYSTEM AND METHOD FOR SOOTHING INFANTS
3y 3m to grant Granted Oct 27, 2026
Patent 12766070
PARTNER TOY FOR MASSAGING A FIRST AND A SECOND PERSON
4y 5m to grant Granted Oct 20, 2026
Patent 12766288
METHODS AND SYSTEMS OF PAVLOVIAN SLEEP INDUCTION
4y 4m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
96%
With Interview (+18.8%)
2y 9m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1186 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month